<DOC>
	<DOCNO>NCT01542450</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial investigate pharmacodynamics pharmacokinetics insulin detemir insulin NPH Japanese subject type 1 diabetes mellitus .</brief_summary>
	<brief_title>Pharmacokinetics Insulin Detemir Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes mellitus HbA1c ( glycosylated haemoglobin ) maximum 9.0 % Duration diabetes least 1 year Body Mass Index ( BMI ) maximum 25.0 kg/m^2 Recurrent severe hypoglycaemia Proliferative retinopathy maculopathy require acute treatment judge Investigator Impaired hepatic function Impaired renal function Cardiac problem Uncontrolled treated / untreated hypertension Hepatitis B surface antigen , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibody , positive Known suspect allergy trial product relate product include component Previous history serious allergy anaphylactic reaction Any disease condition Investigator feel would interfere trial participation evaluation result Severe latephase diabetic complication include nephropathy Blood donation 400 mL ( inclusive ) total within last 12 week 200 mL ( inclusive ) total within last 3 week Known suspected alcohol illicit substance abuse dependence Pregnancy , breastfeeding ( within year labour ) intention become pregnant The receipt investigational drug within last 12 week prior trial Current anticipate treatment systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>